67 episodes

Interviews and highlights from the 2015 ASCO annual meeting.

2015 ASCO Annual Meeting ecancer

    • Medicine

Interviews and highlights from the 2015 ASCO annual meeting.

    • video
    Promising results for nivolumab in advanced liver cancer

    Promising results for nivolumab in advanced liver cancer

    Dr Anthony El-Khoueiry presents at a press conference at ASCO 2015 findings from a phase I/II study that suggest nivolumab is safe and effective in advanced liver cancer.

    • 5 min
    • video
    Nivolumab extends survival for NSCLC

    Nivolumab extends survival for NSCLC

    Dr Luis Paz-Ares presents at ASCO 2015 data from a randomised phase III study that indicate PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small cell lung cancer (NSCLC).

    • 8 min
    • video
    Genomic marker predicts anti-PD-1 response in several cancers

    Genomic marker predicts anti-PD-1 response in several cancers

    Dr Dung T. Le presents, at ASCO 2015, a phase II study that has identified the first genomic marker mismatch repair (MMR) deficiency to predict response to the anti-PD-1 antibody pembrolizumab.

    • 5 min
    • video
    Pembrolizumab for head and neck cancer

    Pembrolizumab for head and neck cancer

    Dr Tanguy Seiwert presents the results of a 132-patient study that indicates that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC) during a press conference at ASCO 2015.

    • 6 min
    • video
    Ibrutinib combination regimen shows substantial benefits in relapsed CLL

    Ibrutinib combination regimen shows substantial benefits in relapsed CLL

    Dr Chanan-Khan talks to ecancertv at ASCO 2015 about his analysis of a large phase III study which suggests that the combination of ibrutinib and bendamustine/rituximab (BR) improves outcomes for patients with chronic-lymphocytic leukaemia (CLL) that has worsened despite prior therapy.

    • 7 min
    • video
    Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

    Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

    Dr Schuchter gives an expert commentary at ASCO 2015 on immunotherapy data presented on the first day:

    - A 132-patient study indicating that pembrolizumab immunotherapy is effective for patients with recurrent or metastatic head and neck cancer (HNC)

    - Genomic marker predicts anti-PD-1 response in several cancers

    - Findings from a phase I/II study that suggest that nivolumab is safe and effective in advanced liver cancer

    - Randomised phase III study indicates PD-1 immunotherapy is an effective treatment option for NSCLC

    • 6 min

Top Podcasts In Medicine

More by ecancer